Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
Hospital Duran i Reynals
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Duran i Reynals (17)
2023
-
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)
Bone Marrow Transplantation
-
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679
2022
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
-
Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC
Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10
2021
-
Lung Cancer in Spain
Journal of Thoracic Oncology
-
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 980-987
2019
-
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
Investigational New Drugs, Vol. 37, Núm. 1, pp. 98-108
2017
2015
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
2011
-
Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry
Breast Cancer Research and Treatment, Vol. 128, Núm. 2, pp. 573-579
-
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
Clinical Cancer Research, Vol. 17, Núm. 5, pp. 1160-1168
2010
-
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328
2009
-
Efficacy and safety of Liposomal cytarabine in lymphoma Patients with central nervous system involvement from lymphoma
Cancer, Vol. 115, Núm. 9, pp. 1892-1898
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2008
-
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study
Haematologica, Vol. 93, Núm. 12, pp. 1829-1836
-
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain
Clinical Cancer Research, Vol. 14, Núm. 9, pp. 2861-2869
2003
-
High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group
Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151